GlassScriptPhysician profile
Dorothy E Parish
NPI 1568928950
$1,289.31
in general payments reported to CMS, 2019-2025
24 companies · $73.09 in 2025
The $73.09 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.46 · 2022: $411 · 2023: $372 · 2024: $407 · 2025: $73.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $154.83 | 2022-2024 | Keytruda |
| Myriad Genetic Laboratories, INC. | $148.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $139.65 | 2024 | Opdivo |
| Horizon Therapeutics Plc | $105.36 | 2023 | Uplizna |
| Tempus Ai, INC | $74.44 | 2024-2025 | Xt Cdx |
| Lilly USA, LLC | $68.27 | 2022-2023 | Jaypirca, Verzenio |
| Janssen Pharmaceuticals, INC | $66.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $64.72 | 2022-2024 | Imfinzi |
| Iovance Biotherapeutics, INC. | $58.10 | 2025 | Amtagvi |
| Acera Surgical, INC. | $57.24 | 2023 | Restrata Wound Matrix |
| Tersera Therapeutics LLC | $50.69 | 2023 | Xermelo, Zoladex |
| Novartis Pharmaceuticals Corporation | $46.52 | 2023-2024 | |
| Acrotech Biopharma INC. | $43.80 | 2024 | Beleodaq |
| Amgen INC. | $35.79 | 2022 | |
| Sobi, INC | $23.73 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $22.68 | 2024 | Exparel |
| Genzyme Corporation | $22.65 | 2024 | |
| Pharmaessentia USA Corporation | $19.20 | 2023 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $16.34 | 2023 | Ninlaro |
| Exelixis INC. | $16.27 | 2022 | |
| Coherus Oncology, INC. | $14.15 | 2024 | |
| Seagen INC. | $14.11 | 2022 | |
| Kci USA, INC. | $13.43 | 2021 | |
| Blueprint Medicines Corporation | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Parish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.